FIFARMA and AFIDRO participate in The Economist’s ‘War On Cancer LATAM’ Event

Last Tuesday, September 18th, the Economist held the “War On Cancer LATAM: Shared Struggles, Collective Success” conference in Bogotá, Colombia. The event was well attended by  leaders of the pharmaceutical industry in Latin America, including pharmaceutical companies executives, public sector representatives (State and National Government officials) and patient organizations.

 

FIFARMA and AFIDRO were main sponsors of the event and actively participated in promoting the dialogue between the different actors. Both institutions had their own stand (booth) at the event, and Mr. Gustavo Morales, Executive President of Afidro, participated in a panel discussion on the importance of engaging finance ministries.

During his presentation, Morales noted: “In Colombia, we choose private companies to manage health, but with public restrictions, and we have not benefited from competition from the private sector.” He also added: “We must agree on health as a fundamental right in Colombia.”

In a similar light, Fernando Fon Mendez, Medical and Regulatory Affairs Director of AMIIF, a member association of FIFARMA, spoke about the importance of cross-sector engagement in Mexico: “Mexico has noticed that it is important to involve different actors, not only health actors, who  allow the creation of an interdisciplinary network to improve the health system.”

During the meeting, the results of a major study on lung cancer in Latin America were also disseminated.

The study, called ‘Lung Cancer in Latin America: Time to Stop Looking Away,’ was developed by The Economist Intelligence Unit with the support of Roche Laboratories, and analyzed data from Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Paraguay, Peru and Uruguay. Their findings indicate that lung cancer has resulted in more than 60,000 deaths each year in these countries, with an annual cost of over US$ 1,600 million.

During the War On Cancer Conference, we saw prominent panelists from the scientific world, pharmaceutical companies, the public sector and from patient organizations united under a common goal: to promote access to health and the possibility of better treatments made available to the entire population.

At the end of the event, Juan Carlos Trujillo, FIFARMA’s Director of Operations and International Policy, concluded: “We are proud to support this type of event where dialogue is facilitated and promoted between the different key players that shape the biopharmaceutical industry.” He added: “Gathering in spaces, such as War On Cancer, where scientific and social conversations converge with the regulatory frameworks of each country in the region, is important to facilitate decision-making and the design of public policies in the biopharmaceutical industry.”

 

Autor: María Alejandra De Guzman – FIFARMA Communications Manager